PEX13 and viral infectious disease: Strikingly, Bcl-xL-TM, VAMP-2-TM or Pex13-TM could not inhibit MAVS activity in inducing IFN production following virus infection (Fig. 3c), nor was MAVS aggregation affected (Fig. 3d).